Veru Inc.

NASDAQ:VERU

Biotechnology

Healthcare
$3.16 +4.33%

+$0.13 today

Market cap
$50.72M
Beta
-1.13
P/E (TTM)
-4.8
EPS (TTM)
-$0.65
52W Low $2.05High $7.33

Volume 0.34M

Average 1.82M

VERU Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Veru Inc.NASDAQ: VERU

Capital Expenditures · Q2 FY2026 · quarter ended Mar 2026

Capital expenditures grows, but more slowly than its trailing trend

Q2 FY2026 capital expenditures of $5 rose 66.7% year over year, behind the +100.0% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at -88.6% a year.

Context

  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +66.7% toward the trailing-twelve-month pace of +100.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5— QoQ
Last fiscal yearSep 2025
-$1.08K-99.3% YoY
LTMMar 2026
$3+100.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.7%——
1 year-99.3%——
3-year CAGR-88.6%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.08K) USD
Year-over-year change
+99.3%

Capital Expenditures vs competitors

How VERU compares with its peers on the latest reported figures

  • VERU's LTM Mar 2026 capital expenditures of $3 is the 3rd largest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of +100.0% is the 2nd highest of 4, against a peer median of +100.0%.
VERU Competitors Peer median
Capital Expenditures for VERU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DYAIDyadic International, Inc.LTM Mar 2026$8 +180.0%—0.0%
ANVSAnnovis Bio, Inc.LTM Mar 2026$5 ———
VERUVeru Inc.LTM Mar 2026$3 +100.0%-88.6%—
CELUCelularity Inc.LTM Dec 2025$1 -100.0%—0.0%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 ———
PYPDPolyPid Ltd.LTM Dec 2025$0 ———
RNXTRenovoRx, Inc.LTM Mar 2026$0 +100.0%—0.0%
Peer median (excluding VERU) $0+100.0%—0.0%

Competitors are the stored peer set for VERU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income7.39M(83.78M)(93.15M)(37.8M)(22.73M)
Depreciation & Amortization211.39K209.6K269.87K268.18K152.11K
Deferred Income Tax(3.57M)76.21K177.5K367.18K(1.92K)
Stock-Based Compensation5.05M11.24M17.92M13.64M8.1M
Change in Working Capital(7.28M)25.88M(15.15M)222.49K(4.13M)
Accounts Receivables(3.56M)4.54M(4.15M)546.2K(657.25K)
Inventory546.38K(3.13M)648.63K986.11K863.93K
Accounts Payables597.1K18.59M(7.43M)(5.43M)(2.76M)
Other Working Capital(4.86M)6.14M(4.22M)4.12M(1.58M)
Other Non-Cash Items(17.38M)(1.14M)1.92M1.62M(11.44M)
Operating Cash Flow(15.57M)(47.51M)(88.01M)(21.68M)(30.04M)
Capital Expenditures(376.65K)(733.05K)(665.7K)(158.32K)(1.08K)
Acquisitions (Net)15M5M0024.75M
Purchases of Investments00000
Sales of Investments0000393.22K
Other Investing Activities007M304.54K0
Investing Cash Flow14.62M4.27M6.33M146.21K25.14M
Debt Repayment(19.44K)(9.09K)132.98K(132.98K)(4.22M)
Common Stock Issued108.1M1.08M6.01M35.3M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.64M04.97M1.66M0
Financing Cash Flow109.72M1.07M11.11M36.83M(4.22M)
Effect of Forex Changes00000
Net Change in Cash108.77M(42.17M)(70.57M)15.29M(9.12M)
Free Cash Flow(15.95M)(48.24M)(88.68M)(21.84M)(30.04M)

Veru Inc.

NASDAQ:VERU

Intrinsic Alpha fair value

Locked

Current Price

$3.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.